- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05188573
EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
Study Overview
Status
Conditions
Detailed Description
This is a prospective longitudinal and interventional study of the Bluestar Genomics early detection pancreatic cancer test. The test will be ordered and results returned to site-investigators. The study is planned to enroll 10,000 male and female, ≥ 50 years of age and newly diagnosed with type II diabetes (within 90 days prior to enrollment). The study population will target 70% of subjects over 65 years old, 53% males and will target to enroll at least 50% of subjects with a BMI <32.
Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis. If test result is "detected", MRI imaging will be performed to further assess the pancreas. If the MRI imaging study results are abnormal, the subject will be referred back to their enrolling clinician for additional diagnostic work up as part of routine healthcare. After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a "not detected" test result.
The study will also include an Bluestar Genomics's test "not detected" imaging arm (negative control imaging arm) for each time point. Subjects included in the negative imaging arm will be pre-specified and randomly selected among the Bluestar Genomics "not detected" cases gender ratio and age matched to Bluestar Genomics "detected" and will undergo MRI imaging.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Judy Sheard, MPH, CCRA
- Phone Number: 858-342-4493
- Email: jsheard@bluestargenomics.com
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- Bluestar Genomics, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥50 years of age or older at the time of enrollment
- Willing to provide and sign the informed consent form
- Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):
- FBG ≥126mg/dl
- HbA1c ≥ 6.5%
- RBG ≥200mg/dl
- 2-hour post-glucose ≥ 200mg/dl (OGTT)
- Must have had glycemic parameter measured in 3-18 months prior to screening without meeting DM criteria
- Must be willing to provide several tubes of blood without endangering health
- No history of pancreatic cancer
- No history of IPMNs, other neoplastic cysts and pancreatitis
- No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated > 1 year prior to enrollment and in situ carcinomas)
Exclusion Criteria:
- Prior DM diagnosis
- Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)
- Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment
- Any known pancreatic lesions
- Received cancer treatment within the past 5 years (with the exception of treatment of non- melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.
- Current chronic or acute oral steroid use
- History of intra-articular steroid injections (<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)
- Any surgery requiring general anesthesia within 2 months of collection
- Local anesthetic (including dental novocaine) within 1 week of collection
- History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)
- Blood transfusion within 1 month
- Organ transplant recipient
- Currently pregnant, or pregnancy within last 12 months
- Receipt of systemic immunomodulation therapy within past 12 months
- Significant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EpiDetect Arm
Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis.
After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a "not detected" test result.
|
Blood collection and pancreatic cancer early detection testing with return of results
|
EXPERIMENTAL: EpiDetect "not detected" MRI Arm
A pre-specified number of cases with test results "not detected" will be randomly selected, gender ratio and age matched to subjects with test results "detected" and will undergo MRI imaging at T0 (n=226), at T1 (n=208 ) at T2 (n=208 ) and 24 months (n=208) from diabetes diagnosis.
|
Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical performance of test: pancreatic cancer sensitivity
Time Frame: 24 months or until diagnostic resolution
|
Test sensitivity (Sn) for histopathology confirmed pancreatic cancer (ground truth)
|
24 months or until diagnostic resolution
|
Clinical performance of test: IPMNs sensitivity
Time Frame: 24 months or until diagnostic resolution
|
Test sensitivity (Sn) for intraductal papillary mucinous neoplasms (IPMNs)
|
24 months or until diagnostic resolution
|
Clinical performance of test: Specificity
Time Frame: 24 months or until diagnostic resolution
|
Test specificity (Sp) for pancreatic neoplasia.
|
24 months or until diagnostic resolution
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive Predictive Value
Time Frame: 24 months or until diagnostic resolution
|
PPV for pancreatic neoplasia
|
24 months or until diagnostic resolution
|
Negative Predictive Value
Time Frame: 24 months or until diagnostic resolution
|
NPV
|
24 months or until diagnostic resolution
|
Stage Shift
Time Frame: 24 months or until diagnostic resolution
|
Evaluation of stage at diagnosis
|
24 months or until diagnostic resolution
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EpiDetect
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
Clinical Trials on Early detection pancreatic cancer test
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityShanghai Weihe Medical Laboratory Co., Ltd.Not yet recruitingPRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection (PROFUTURE)Neoplasms | CancerChina
-
GRAIL, LLCRecruitingCancer | Early Detection of CancerUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Guangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Cancer Institute and Hospital, Chinese Academy...Guangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Zhujiang HospitalGuangzhou BRCompletedHepatobiliary MalignanciesChina
-
GRAIL, LLCCompleted
-
Shanghai Zhongshan HospitalGuangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Shanghai Zhongshan HospitalGuangzhou Burning Rock Dx Co., Ltd.Completed
-
Fudan UniversityGuangzhou Burning Rock Bioengineering Ltd.Active, not recruiting